HOPO Therapeutics

HOPO Therapeutics is a clinical-stage pharmaceutical company leveraging its world-class expertise to develop treatments for heavy metal poisoning and to pioneer novel methods for directed radioisotope delivery. The companys orally-available flagship drug candidate HOPO-101 is a heavy metal chelating agent positioned to become the best-in-class solution for significant unmet needs in lead poisoning and other forms of heavy metal toxicity, as well as nuclear and radiological threat readiness. HOPO-101 has been well-tolerated in an ongoing Phase 1 safety study, and has shown superior pre-clinical efficacy compared to the standard-of-care medical countermeasure. Further development of this chelating agent into a delivery...

Women's and children's health,global environmental health,lead poisoning,heavy metal toxicity,and health security

Hopo therapeutics operates in the Biotechnology research industry.

Hopo therapeutics's revenue is 11m - 100m

Hopo therapeutics has 11 - 50 employees.